

## DOCTORAL THESIS

### Anticancer efficacy and mechanism of action studies of the potent plant cycloheptapeptide compounds mavacyocines

Xia, Yixuan

*Date of Award:*  
2020

[Link to publication](#)

#### General rights

Copyright and intellectual property rights for the publications made accessible in HKBU Scholars are retained by the authors and/or other copyright owners. In addition to the restrictions prescribed by the Copyright Ordinance of Hong Kong, all users and readers must also observe the following terms of use:

- Users may download and print one copy of any publication from HKBU Scholars for the purpose of private study or research
- Users cannot further distribute the material or use it for any profit-making activity or commercial gain
- To share publications in HKBU Scholars with others, users are welcome to freely distribute the permanent URL assigned to the publication

# ABSTRACT

## Background

Over the past 200 years, much attention has been paid to natural products for their great contribution in the industry of drug development as many of them have been shown effective against various diseased conditions in humans by virtue of their structural diversity and biological potency. Therefore, they are undeniably a rich resource for the discovery of novel bioactive compounds. To date, many of the mainstay anticancer agents often lead to undesirable side effects and/or develop rapid emergence of drug resistance. Therefore, new therapeutic remedies are desperately needed.

In fact, many active compounds are derived from macrocyclic natural products. The identification of their molecular targets may assist researchers to synthesize biological agents for combating particular diseased conditions. Cycloheptapeptides that modulate specific molecular pathways in suppressing the proliferation of cancer cells are potential candidates for anticancer therapeutics and/or chemopreventive agents. In the current research project, we have demonstrated that MV-A, a novel cycloheptapeptide with the unique amino acid DMCPA isolated from *Maytenus variabilis* (Loes.) C. Y. Cheng (Celastraceae), showed potent cytotoxic activities against a panel of human cancer cell lines, and is worthy for further investigation.

## Objectives

The objectives of this study were to i) evaluate the anticancer effect, ii) elucidate the mechanism of action, and iii) identify the binding target(s) of the natural cycloheptapeptide MV-A.

## Methods

We first carried out various kinds of cellular and animal studies for validating the *in vitro* and *in vivo* anticancer efficacy of MV-A. Next, we performed a number of

bioassays to ascertain the inhibitory effect of MV-A on several major cancer-associated pathways, including apoptosis, cell cycle arrest, senescence and metastasis. The biochemical assays included sulforhodamine B colorimetric assay, flow cytometric analyses of apoptosis and cell cycle arrest, Western blotting, real-time polymerase chain reactions (qPCR) arrays, senescence-associated  $\beta$ -galactosidase staining, phospho-specific protein arrays, as well as migration and invasion staining experiments. Lastly, we also identified the potential protein targets of MV-A by biochemical means, particularly the drug affinity responsive target stability (DARTS) approach.

## **Results**

MV-A is a potent anti-proliferative agent against a variety of cancer cells. It inhibited the proliferation of the human colorectal carcinoma (CRC) HCT116 cells with an  $IC_{50}$  value of 2.28 nM. However, the application of MV-A at 2.68 nM did not induce significant apoptosis; rather it caused a notable cell-cycle arrest at the G1 phase. Moreover, the treatment with this compound (0.68 to 2.68 nM) led to a remarkable senescence in cancer cells as well as a mitigated cellular migration. Meanwhile, the expression levels of some components of the p16 cascade and PI3K-AKT pathway, so as several epithelial-to-mesenchymal transition (EMT) molecules were suppressed by MV-A. Furthermore, HSP90, calnexin, EF2, 14-3-3 and annexin A1 were identified as the direct binding targets of MV-A in our DARTS analysis.

## **Conclusions**

In the present study, our results indicated that the novel cycloheptapeptide MV-A inhibited proliferation and migration of CRC HCT116 cells via the induction of cellular senescence and modulation of multiple pathways, including the p16/Rb, PI3K-AKT and EMT signaling pathways. These results revealed a potential role of MV-A in cancer therapy. The direct binding targets of MV-A further uncovered its molecular actions

against different diseased conditions. Our findings strongly support the development of MV-A as a therapeutic agent for combating cancerous pathologies, explicitly CRC.

**Keywords:** Plant natural products, colorectal carcinoma, cycloheptapeptide, anticancer, cellular senescence, PI3K-AKT pathway, EMT, binding targets.

# TABLE OF CONTENTS

DECLARATION .....	i
ABSTRACT.....	ii
ACKNOWLEDGEMENTS .....	v
TABLE OF CONTENTS.....	vi
LIST OF TABLES .....	x
LIST OF FIGURES .....	xi
LIST OF ABBREVIATIONS.....	xiv
<b>CHAPTER 1 .....</b>	<b>1</b>
ABSTRACT.....	2
1. Introduction .....	3
2. Marine-Derived Anticancer Cyclopeptides.....	5
2.1 Anticancer Cyclopeptides Derived from Sponge .....	5
2.2 Anticancer Cyclopeptides Derived from Ascidians/ Tunicates.....	18
2.3 Anticancer Cyclopeptides Derived from Mollusks .....	22
2.4 Anticancer Cyclopeptides Derived from Marine Algae .....	26
3. Terrestrial plant-Derived Anticancer Cyclopeptides .....	29
4. Bacteria-Derived Anticancer Cyclopeptides.....	40
4.1 Anticancer Cyclopeptides Derived from Non-Marine Bacteria .....	40
4.2 Anticancer Cyclopeptides Derived from Marine Bacteria .....	42
4.3 Anticancer Cyclopeptides Derived from Cyanobacteria .....	48
5. Conclusions and future perspectives .....	70
<b>CHAPTER 2.....</b>	<b>72</b>
ABSTRACT.....	73
1. Introduction .....	74
2. Material and methods .....	78
2.1 Materials .....	78
2.2 Methods .....	79
3. Results .....	82
3.1 The three cyclopeptides showed potent activity against cancer cells.....	82
3.2 MV-A inhibits cancer cell growth.....	84
3.3 MV-A is cytotoxic to HCT116 colorectal cancer cells .....	86
3.3 MV-A treatment leads to tumor regression in the HCT116 carcinoma	

xenograft mouse models .....	88
4. Discussion .....	92
5. Conclusion.....	97
<b>CHAPTER 3.....</b>	<b>98</b>
ABSTRACT .....	99
1. Introduction .....	100
2. Material and methods .....	101
2.1 Cell viability assay .....	101
2.2 Flow cytometric analysis .....	101
2.3 Cell cycle analysis .....	101
2.4 Western blot analysis.....	102
2.5 Senescence staining .....	102
2.6 RT <sup>2</sup> Profiler PCR array.....	102
2.7 Phospho-antibody array .....	103
2.8 Statistical analysis .....	104
3. Results .....	104
3.1 Cytotoxicity .....	104
3.2 Effect of MV-A on induction of apoptosis of HCT116 cancer cells.....	106
3.3 Effect of MV-A on cell cycle regulation in HCT116 cancer cells .....	110
3.4 MV-A elicited cellular senescence .....	112
3.5 MV-A Targeted the p16/pRb Signaling Pathways .....	114
3.6 MV-A inhibited colon cancer cell proliferation via inhibiting the PI3K- AKT signaling .....	118
4. Discussion .....	128
5. Conclusion.....	133
<b>CHAPTER 4.....</b>	<b>134</b>
ABSTRACT .....	135
1. Introduction .....	136
2. Material and methods .....	138
2.1 Scratch wound assay.....	138
2.2 Transwell migration assay .....	139
2.3 Transwell invasion assay .....	139
2.4 RT <sup>2</sup> Profiler PCR array.....	140
2.5 Western blot analysis.....	140

2.6 Statistical analysis .....	141
3. Results .....	141
3.1 MV-A reduced cellular mobilization and migration in colorectal cancer cells .....	141
3.2 MV-A inhibited cell invasion in colon cancer cells .....	146
3.3 MV-A inhibited the epithelial-mesenchymal transition (EMT) pathway .....	148
4. Discussion .....	153
5. Conclusion.....	157
<b>CHAPTER 5.....</b>	<b>158</b>
ABSTRACT.....	159
1. Introduction .....	160
2. Material and methods .....	164
2.1 Materials .....	164
2.2 DARTS proteolysis .....	165
2.3 Identification of potential protein targets .....	166
3. Results .....	167
4. Discussion .....	175
5. Conclusion.....	181
<b>CHAPTER 6.....</b>	<b>182</b>
1. Conclusions .....	183
2. Future prospects .....	187
REFERENCES .....	189
CURRICULUM VITAE.....	212
Publications .....	210
Conference posters and presentations .....	210